This company has been marked as potentially delisted and may not be actively trading. GlycoMimetics (GLYC) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock GlycoMimetics (NASDAQ:GLYC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.70%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$3.54MNumber OfInsiders Selling(Last 3 Years)3Amount OfInsider Selling(Last 3 Years)$3.06M Get GLYC Insider Trade Alerts Want to know when executives and insiders are buying or selling GlycoMimetics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GLYC Insider Buying and Selling by Quarter GlycoMimetics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/7/2024Public Equities L.P. InvusMajor ShareholderSell614$18.00$11,052.00 8/5/2024Public Equities L.P. InvusMajor ShareholderSell1,645$19.00$31,255.00 8/1/2024Public Equities L.P. InvusMajor ShareholderSell635$22.00$13,970.00 7/29/2024Public Equities L.P. InvusMajor ShareholderSell3,639$24.00$87,336.00 7/26/2024Public Equities L.P. InvusMajor ShareholderSell2,583$24.00$61,992.00 6/20/2024Edwin RockInsiderBuy1,900$25.00$47,500.00 9/21/2023Edwin RockInsiderBuy350$138.00$48,300.00 5/17/2023Brian M HahnCFOSell37$195.00$7,215.00 5/10/2023Daniel M JuniusDirectorBuy300$156.00$46,800.00 5/8/2023Bruce S JohnsonSVPBuy135$157.00$21,195.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/23/2023Public Equities L.P. InvusMajor ShareholderBuy2,000$175.00$350,000.00 2/21/2023Public Equities L.P. InvusMajor ShareholderBuy500$185.00$92,500.00 2/17/2023Public Equities L.P. InvusMajor ShareholderBuy2,000$171.00$342,000.00 2/15/2023Public Equities L.P. InvusMajor ShareholderBuy10,000$216.00$2,160,000.00 2/9/2023Public Equities L.P. InvusMajor ShareholderBuy114$324.00$36,936.00 1/25/2023Scott D SandellMajor ShareholderSell6,520$326.00$2,125,520.00 1/5/2023Scott D SandellMajor ShareholderSell713$276.00$196,788.00 1/3/2023Scott D SandellMajor ShareholderSell1,748$299.00$522,652.00 12/22/2022Edwin RockInsiderBuy1,100$225.00$247,500.00 11/14/2022Edwin RockInsiderBuy1,000$143.00$143,000.00 (Data available from 1/1/2013 forward) GLYC Insider Trading Activity - Frequently Asked Questions Who is on GlycoMimetics' Insider Roster? The list of insiders at GlycoMimetics includes Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, Public Equities L.P. Invus, and Scott D Sandell. Learn more on insiders at GLYC. What percentage of GlycoMimetics stock is owned by insiders? 8.70% of GlycoMimetics stock is owned by insiders. Learn more on GLYC's insider holdings. Which GlycoMimetics insiders have been buying company stock? The following insider purchased GLYC shares in the last 24 months: Edwin Rock ($95,800.00). How much insider buying is happening at GlycoMimetics? Insiders have purchased a total of 2,250 GLYC shares in the last 24 months for a total of $95,800.00 bought. Which GlycoMimetics insiders have been selling company stock? The following insider sold GLYC shares in the last 24 months: Public Equities L.P. Invus ($205,605.00). How much insider selling is happening at GlycoMimetics? Insiders have sold a total of 9,116 GlycoMimetics shares in the last 24 months for a total of $205,605.00 sold. GlycoMimetics Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Compensation: $1.13MMs. Rachel K. King (Age 65)Co-Founder & Director Compensation: $40kMr. Brian M. Hahn (Age 50)Senior VP & CFO Compensation: $822.12kDr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Compensation: $677.4kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical Operations More Insider Trading Tools from MarketBeat Related Companies Coeptis Therapeutics Insider Trades ALX Oncology Insider Trades Ovid Therapeutics Insider Trades Mersana Therapeutics Insider Trades Rani Therapeutics Insider Trades Xilio Therapeutics Insider Trades MEI Pharma Insider Trades Karyopharm Therapeutics Insider Trades Clearside Biomedical Insider Trades Synergy CHC Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:GLYC) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
